We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Coated Dialysis Catheter Reduces Thrombus Formation

By HospiMedica International staff writers
Posted on 31 Mar 2010
A new catheter for patients on long-term hemodialysis prevents thrombus accumulation with the aid of a biomimetic coating that discourages clot formation.

The Duraspan biomimetic coated-hemodialysis catheter is intended for both short and long term (over 30 days) vascular access for hemodialysis, hemoperfusion, or apheresis therapy. More...
Access is attained via the internal jugular vein, external jugular vein, subclavian vein, or femoral vein. The hemodialysis catheter is covered with novel surface coating on both the inner and outer surfaces that mimics the glycocalyx layer found on natural endothelial tissue surfaces in vessel walls, thereby reducing thrombus accumulation by 87%. Additional features include staggered tip spacing for reduced recirculation and a reverse-cut proximal lumen designed to maintain patency even when flush with the vessel wall. The catheter also includes a white retention cuff for tissue ingrowth, used to anchor the catheter.

To reduce recirculation and deliver a high rate of flow (exceeding 500 mL/minute), the catheter takes advantage of cardiovascular blood flow dynamics; the distal aperture returns blood to the right atrium, while the proximal opening draws blood from the superior vena cava. For easier identification, the proximal lumen is marked by a red connector and the distal lumen (blood return) is marked by a blue connector. The catheter comes in two versions: the Duraspan with a 3.5 cm tip stagger, and the Duraspan Ultra with a 7 cm tip stagger, each available in multiple lengths for patient specificity. The Duraspan and Duraspan Ultra Catheters are products of r4 Vascular (Maple Grove, MN, USA).

"Physicians have long thought that if one was able to make the catheter less recognizable as a foreign object in the body it could revolutionize catheter-based hemodialysis,” said Don Geer, president and CEO of r4 Vascular. "Developing the catheter, r4 Vascular engineers utilized stealth coating technologies, approaching the thrombus problem by camouflaging the catheter in a biomimetic coating.”

Studies have shown almost 30% of prevalent hemodialysis patients use catheters for vascular access, despite the fact that catheter complications are a major cause of morbidity and mortality for hemodialysis patients and increase the burden on the health care system.

Related Links:

r4 Vascular



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.